MedDRA

MedDRA
Name	MedDRA
Type	Clinical terminology
Origin	International
Governing body	International Council for Harmonisation
First release	1999
Latest release	2026

MedDRA is a standardized medical terminology for regulatory communication and evaluation of medical products and medical device events. It facilitates coding of adverse event reports, clinical trial data, and pharmacovigilance across multinational agencies such as European Medicines Agency, Food and Drug Administration, World Health Organization, Pharmaceutical Research and Manufacturers of America, and Council of Europe. Adopted by regulatory authorities, industry stakeholders, and academic centers including Harvard University, Oxford University, Johns Hopkins University, Karolinska Institutet, and University of Tokyo, it underpins harmonized safety surveillance and labeling activities.

Introduction

MedDRA provides a multilingual, clinically oriented set of terms that supports signal detection and regulatory submissions to organizations such as International Council for Harmonisation, European Medicines Agency, Pharmaceutical and Medical Devices Agency, Food and Drug Administration, and World Health Organization. Users from pharmaceutical companies like Pfizer, Roche, Novartis, GlaxoSmithKline, and AstraZeneca and contract research organizations such as IQVIA and Parexel employ the terminology for coding adverse events, concomitant conditions, and clinical trial endpoints for regulators including Health Canada, Therapeutic Goods Administration, and Swissmedic.

History and Development

Work on the terminology began in the late 1990s under the auspices of multinational stakeholders including International Council for Harmonisation, European Federation of Pharmaceutical Industries and Associations, and national regulators like Food and Drug Administration and European Medicines Agency. Its initial releases reflected consensus from pharmaceutical companies, regulatory agencies, and academic groups at conferences like the DIA Global Annual Meeting and workshops convened with contributors from WHO Collaborating Centre for International Drug Monitoring. Subsequent expansions incorporated inputs referenced in guidances influenced by legal frameworks such as the Food and Drug Administration Modernization Act and initiatives tied to post-marketing surveillance programs coordinated with networks like Sentinel Initiative and consortia such as TransCelerate Biopharma.

Structure and Hierarchy

The terminology is organized into a five-level hierarchy designed for specificity and aggregation: System Organ Classes, High Level Group Terms, High Level Terms, Preferred Terms, and Lowest Level Terms. This hierarchical design supports mapping to classification systems and ontologies used by institutions such as National Library of Medicine, UMLS Metathesaurus, SNOMED CT partners, and linkage projects involving Observational Health Data Sciences and Informatics. The System Organ Classes align conceptually with anatomical and pathological groupings familiar to clinicians at centers like Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, and Imperial College London; Preferred Terms provide clinician-facing labels used in case narratives submitted to agencies like European Medicines Agency and Food and Drug Administration.

Maintenance and Governance

Ongoing maintenance is overseen by the maintenance organization chartered under the International Council for Harmonisation structure and includes representatives from regulatory agencies such as Food and Drug Administration and European Medicines Agency, industry bodies like Pharmaceutical Research and Manufacturers of America, and academic advisors from institutions like Stanford University and University of Cambridge. Annual updates and revision proposals are processed via working groups, public consultations, and special interest teams collaborating with stakeholders including World Health Organization, European Centre for Disease Prevention and Control, and patient advocacy organizations that interface with regulators such as Health Canada. Licensing, distribution, and training activities are managed in partnership with vendors and standards organizations including ISO-aligned committees and professional societies that host educational sessions at meetings such as the International Society of Pharmacovigilance annual congress.

Applications and Use Cases

MedDRA is used in adverse event reporting to regulators like Food and Drug Administration, signal detection operations at agencies such as European Medicines Agency, and data submissions from pharmaceutical sponsors including Bristol Myers Squibb, Eli Lilly and Company, Sanofi, and Takeda. Clinical trial data management platforms from vendors working with trial sites like Mayo Clinic and academic research networks such as ClinicalTrials.gov employ the terminology for endpoint coding. Electronic health record integration efforts led by initiatives involving HL7 International, Observational Health Data Sciences and Informatics, and national health systems including NHS England and Veterans Health Administration leverage MedDRA mappings for pharmacovigilance, real-world evidence projects, and post-marketing safety studies coordinated with consortia like European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.

Criticisms and Limitations

Critiques raised by academic groups at Johns Hopkins University, University of Oxford, and independent researchers cite concerns about cost and licensing barriers for some academic and small-business users compared to open terminologies used by National Library of Medicine projects; issues of granularity and mapping to clinical coding standards such as ICD-10 and SNOMED CT have been discussed at forums including meetings of HL7 International and workshops hosted by EMA. Additional limitations include challenges in cross-map consistency highlighted by investigators at Harvard Medical School and interoperability projects tied to Observational Health Data Sciences and Informatics, and debates about governance transparency that surfaced in stakeholder consultations involving European Federation of Pharmaceutical Industries and Associations and patient groups supported by European Patients' Academy.

Category:Medical terminology